Phaseline

Companies › ReacX Pharmaceuticals

ReacX Pharmaceuticals: clinical trials, targets and expected readouts

1 active drug program in 2 registered trials: 1 Phase 1, 1 Phase 3; Psychiatry; next expected readout Dec 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Nalmefene
Mu opioid receptor antagonist; Delta opioid receptor antagonist; Kappa opioid receptor partial agonist
OPRM1, OPRD1, OPRK1Phase 1Opioid Abuse and Addiction; Behavioural AddictionDec 2026

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07325279NalmefenePhase 1Opioid Abuse and AddictionPsychiatryDec 2026
NCT05540288NalmefenePhase 3Behavioural AddictionPsychiatryJul 2027

Targets

OPRM1 (1) OPRD1 (1) OPRK1 (1)

Companies with the same targets

Trevi Therapeutics Currax Pharmaceuticals AgelessRx Akyso Therapeutics Adneuris Therapeutics Alkermes Boulder Care Inventage Lab. Shionogi Ensysce Biosciences

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.